Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME
Status:
Completed
Trial end date:
2017-09-12
Target enrollment:
Participant gender:
Summary
To explore a more clinical feasible treatment regime with ranibizumab for DME to provide
satisfactory treatment effect with a lower number of visits and injections.